News for Verastem, Inc. (VSTM)

FibroGen (FGEN) has appointed Dr. Michael Kauffman to its Board of Directors, effective June 4, 2025. Dr. Kauffman brings 30 years of life sciences industry

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Monday. The Dow traded down 0.49% to 42,064.07 while the NASD...

In the opening quarter of 2025, Verastem (VSTM) Oncology has achieved significant milestones in its pipeline initiatives. The company has exercised an early opt

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann

Verastem Oncology (VSTM) reports Q1 2025 results with a slight EPS miss.

Learn about Verastem's (VSTM) recent filing to sell 3.43M shares of common stock.

B. Riley has elevated its price target for Verastem (VSTM) from $12 to $13, maintaining a Buy rating on the stock. The upward revision comes as Verastem announc

On May 9, 2025, HC Wainwright & Co. analyst Sean Lee maintained a "Buy" rating on Verastem (VSTM). The financial services firm raised its price target for VSTM

RBC Capital's analyst has elevated Verastem's (VSTM) price target from $14 to $16 while maintaining an Outperform rating on its stock. This upgrade reflects Ver

Jefferies analyst Kelly Shi has boosted the price target for Verastem (VSTM) to $19 from the previous $15 while maintaining a Buy rating on the company's stock.

Verastem (VSTM) has announced a conference call slated for May 1 at 11 a.m., featuring its President & CEO, Paterson, along with Chief Scientific Officer, Pacht

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann

Overview of BlackRock's Recent Transaction On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a strategic acquisition by adding 77,131 shares of Ve

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann

Key Highlights: Verastem Oncology's new drug targets the KRAS G12D mutation with FDA approval. Analysts predict a significant upside potential for Verast

WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the ”œCompany” or ”œWerewolf”) ( HOWL), an innovative biopharmaceutica

Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.

Jefferies initiates coverage on Verastem (VSTM) with a

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...